ASX Slides as Traders Cash In on Three‑Day Rally
Australian shares fell on the closing bell as the ASX 200 ended a three‑day winning streak, trimming gains but still posting a modest weekly rise.
Index reverses gains amid U.S. rate‑policy surprise
The benchmark index closed down 0.78% on Thursday, wiping out most of yesterday’s advance and leaving the market 1.46% higher over the past five days. The pullback came after Wall Street opened lower, with all three major U.S. indices shedding value following a vote by the Federal Reserve that kept interest rates steady at 3.5%‑3.75%.
Three Fed governors broke ranks and voted for a quarter‑point hike, marking the first three‑way dissent in the same direction since 2016. While the decision itself was modest, the split signaled renewed concern over inflation and prompted traders to reassess risk exposure.
Oil prices also rose, driven by fresh tensions surrounding the Iran‑U.S. situation. Brent crude nudged back toward $89 a barrel, adding pressure on equity markets that are already sensitive to commodity swings.
Australian investors reacted swiftly, with the sell side of the market outpacing buyers. Only the information technology and energy sectors managed to stay above the broader decline, each holding a slight edge over the broader sell‑off.
Related: Godolphin confirms copper gold model at Goodrich
Earnings updates from major listed companies
Domino’s Pizza (ASX:DMP) reported a mixed fiscal year‑26 result. Same‑store sales fell across the board, with Australia‑New Zealand down 4.7% and Asian locations slipping 6.7%. Despite a franchisee‑driven profit boost of 11.3%, the company recorded a statutory loss after write‑downs of $259 million, most of which were non‑cash. The stock surged 8.5% after the announcement.
Energy firm Ampol (ASX:ALD) benefited from higher oil prices, expanding refining margins at its Lytton plant from $8.71 to $28.26 per barrel in the first half of FY 26—a rise of more than 200%. Production volumes grew 8.7%, while fuel sales rose modestly. EBITDA climbed from $649 million to $1.6 billion, and the share edged up 0.52%.
Biotech Mesoblast (ASX:MSB) saw its flagship drug Ryoncil generate $115 million in net revenue for its first full year on the market, with a 37% jump in the second half of the fiscal year. The company also secured a worldwide license for a CAR‑MSC platform targeting several autoimmune diseases, and it announced FDA clearance for a trial in Duchenne muscular dystrophy. The stock slipped 0.25%.
Other market movers included Kip McGrath Education Centres (ASX:KME), which received a 62% premium unsolicited offer from Crimson Consulting Australia, and Dataworks (ASX:DWG), which posted an 81.4% increase in quarterly customer receipts.
These company‑specific developments illustrate how earnings and strategic moves continue to shape individual stock performance even as broader market sentiment turns cautious.
Related: Medical Contract Manufacturing Checklist: Compliance and Quality
Volatile oil markets and geopolitical friction could keep Australian equities on the defensive.
Market outlook and trader sentiment
Analysts note that the recent correction in the Nasdaq 100, now more than 11% below its June peak, reflects a broader risk‑off mood that is spilling over into the Australian market. The mixed signals from U.S. policymakers have heightened uncertainty, prompting many to shift toward cash or lower‑volatility assets.
Some traders remain skeptical about the durability of the week’s modest gains. The market’s ability to sustain its positive trajectory may be tested if inflation pressures prompt another round of rate hikes later in the year.
The pullback highlights the market’s sensitivity to external shocks. The next trading session will likely reveal whether the index can rebound or if the current caution will deepen.
